Clinical Trial Update: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating MVX-220 for safety and efficacy in Angelman syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• MVX-220

Snippet

Sponsor: MavriX Bio, LLC | Conditions: Angelman Syndrome | Phase 1, Phase 2 | Status: RECRUITING